- QIAGEN (QGEN) Backs New AAP Guidelines Supporting QFT-Plus Test QIAGEN (QGEN) supports the new TB screening guidelines from AAP, recommending IGRA tests like QFT-Plus to screen at-risk children of all ages.
Zacks • 19 hours ago
QGEN -0.02% RMD -
- QIAGEN welcomes new U.S. guidelines for use of QuantiFERON-TB Gold Plus in detecting tuberculosis infections in children American Academy of Pediatrics in the United States now recommends IGRA tests like QuantiFERON-TB Gold Plus to screen at-risk children of all ages // New recommendation joins trend of U.S. tuberculosis control guidelines that emphasize use of modern blood-based tests to combat the spread of potentially deadly bacterial infectionGermantown, Maryland, and Venlo, the Netherlands, June 27, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it welcomes ne
GlobeNewswire • yesterday
QGEN -0.02% - QIAGEN's (QGEN) New QCI Interpret Release Enhances AI Functions QIAGEN's (QGEN) latest QCI Interpret release improves the performance of high-throughput NGS labs.
Zacks • 9 days ago
QGEN -0.02% RMD - QIAGEN (QGEN) Debuts dPCR Microbial DNA Detection Assays QIAGEN (QGEN) launches new QIAcuity dPCR assays for microbial applications, enhancing infectious disease research and surveillance.
Zacks • 11 days ago
QGEN -0.02% RMD -
GlobeNewswire • 11 days ago
QGEN -0.02% -
- QIAGEN’s software QCI Interpret accelerates clinical reporting turnaround time for high throughput NGS testing labs Latest QCI Interpret release enhances performance of high-throughput NGS labs, improving turn-around time, diagnostic yield and quality of results // New features include bulk variant assessment, flagging of co-occurring variants and improved muti-user functionality for faster and more efficient workflows // Genomics are moving towards analyzing large, comprehensive gene panels, creating a need for enhanced scalabilityVenlo, the Netherlands, and Redwood City, California, June 13, 2024 (GLOBE NEW
GlobeNewswire • 15 days ago
QGEN -0.02% - QIAGEN publishes 2023 sustainability report, highlighting progress on ESG goals and commitment to sustainable growth ESG commitments recognized as strategic business investments bringing value to stakeholders, including customers and employees // Environment: 15% reduction in Scope 1 and 2 emissions in 2023 through green energy procurement, complemented by 7% decrease in plastic usage // Social: // Leveraging partnerships, QIAGEN broadens diagnostic access worldwide // Commits to goal of at least 40% women in leadership by 2027 // Governance: New Supplier Code of Conduct and Human Rights Committee, upholding h
GlobeNewswire • 16 days ago
QGEN -0.02% - QIAGEN launches new QIAcuity digital PCR assays for microbial applications, enhancing infectious disease research and surveillance 35 new wet-lab tested digital PCR Microbial DNA Detection Assays on research platform GeneGlobe target a wide range of pathogens causing tropical diseases, sexually transmitted and urine tract infections // QIAcuity digital PCR technology enables precise and sensitive detection of pathogens, supporting infectious disease research and public health efforts // New assays add to QIAGEN’s comprehensive portfolio for microbial research showcased at ASM Microbe conference from June 13-17Venlo, the Net
GlobeNewswire • 17 days ago
QGEN -0.02% - QIAGEN (QGEN) Unveils dPCR Tool, Enhances GeneGlobe Platform QIAGEN (QGEN) launches the digital PCR Assay Design Tool for QIAcuity and expands the customization capabilities of its GeneGlobe research platform.
Zacks • 18 days ago
QGEN -0.02% -
- Editas (EDIT) Down 2.3% Since Last Earnings Report: Can It Rebound? Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks • 21 days ago
EDIT QGEN -0.02% - QIAGEN to discontinue NeuMoDx integrated PCR testing system, support customers during transition period NeuMoDx 96 and NeuMoDx 288 Molecular Systems decision taken in light of challenging post-pandemic market development trends // Reaffirms Q2 2024 outlook, raises full-year 2024 outlook for adjusted diluted EPS to $2.14 CER, has started discussions with NeuMoDx customers to assess impact on 2024 sales // Restructuring charge of approximately $400 million – including about $300 million of non-cash charges – planned to be recognized primarily in 2024Venlo, the Netherlands, June 06, 2024 (GLOBE NEWSW
GlobeNewswire • 22 days ago
QGEN -0.02% - QIAGEN launches digital PCR Assay Design Tool for QIAcuity, expands customization capabilities of its research platform GeneGlobe New QIAcuity digital PCR Custom Assay Design Tool for copy number variation analysis supports researchers’ customization needs, complementing QIAGEN’s existing pre-designed assays // GeneGlobe Design and Analysis Hub receives further enhancements, improving user experience and capabilities to design panels collaboratively // Advancements strengthen QIAGEN as a trusted partner for researchers, catering to their diverse needs to further accelerate drug discovery and other applicationsVenlo, the Ne
GlobeNewswire • 23 days ago
QGEN -0.02% - Why Is Rocket Pharmaceuticals (RCKT) Down 4.8% Since Last Earnings Report? Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks • 23 days ago
RCKTW QGEN -0.02% -
- QIAGEN's (QGEN) New Launch Expands US Syndromic Testing Menu QIAGEN's (QGEN) new QIAstat-Dx Gastrointestinal Panel 2 offers fast and accurate identification of up to 16 common gastrointestinal pathogens.
Zacks • 23 days ago
QGEN -0.02% - QIAGEN (QGEN) Advances Precision Medicine With New QIAseq Kit QIAGEN (QGEN) launches the new QIAseq Multimodal DNA/RNA Lib Kit, facilitating multiomic studies and advancing precision medicine.
Zacks • 25 days ago
QGEN -0.02% RMD - QIAGEN expands QIAstat-Dx syndromic testing menu in the U.S. with launch of molecular test to improve gastrointestinal care U.S. FDA clears QIAstat-Dx Gastrointestinal Panel 2 for use in clinical settings // New panel offers fast and accurate identification of up to 16 common gastrointestinal pathogens // Generates results in about one hour based on real-time PCR technology, easy access to Ct values and amplification curvesGermantown, Maryland, and Venlo, the Netherlands, June 03, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAstat-Dx Gastrointestinal
GlobeNewswire • 26 days ago
QGEN -0.02% - QIAGEN (QGEN) Develops Test for Research and CDx Application QIAGEN's (QGEN) next-generation sequencing test aims to aid personalized medicine research in solid tumor types, including ovarian cancer, and improve decentralized testing capabilities.
Zacks • 28 days ago
QGEN -0.02% MYGN +0.62% -
- QIAGEN and Myriad Genetics develop distributable hom*ologous recombination deficiency test for global research and companion diagnostics applications Next-generation-sequencing-based hom*ologous recombination deficiency (HRD) assay based on QIAGEN’s QIAseq xHYB technology, QIAGEN Digital Insight solutions, and Myriad’s proprietary, FDA-approved MyChoice CDx® biomarkers QIAGEN to make kit-based HRD test available globally to support research and companion diagnostics development in collaboration with pharmaceutical partners enabling wider adoption and potential clinical indication expansion for MyChoice CDx Project builds on recently announced
GlobeNewswire • 29 days ago
QGEN -0.02% MYGN +0.62% - QIAGEN launches new library preparation kit, facilitating multiomic studies and advancing precision medicine QIAseq Multimodal DNA/RNA Lib Kit enables streamlined DNA and RNA library preparation for next-generation sequencing from a single sample // New kit advances precision medicine by facilitating multiomic studies and Comprehensive Genomic Profiling, crucial for understanding complex diseases like cancer // Researchers are provided with the first multimodal sequencing kit for multiple sample types, offering high flexibility and sensitivity, saving sample material and timeVenlo, the Netherlands, May
GlobeNewswire • 30 days ago
QGEN -0.02% - Qiagen (QGEN) Up 1.6% Since Last Earnings Report: Can It Continue? Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks • 30 days ago
QGEN -0.02% BIIB
